Tetrous has completed the first surgical cases using EnFix TAC, its latest product that expands its line of EnFix implants to cover every surgical technique for rotator cuff repair. The EnFix product line is specifically designed to address Enthesis Failure Syndrome.
EnFix technology utilizes proprietary demineralized cortical bone fibers to yield an osteoinductive and osteoconductive implant designed to support optimal biologic healing at the bone-to-tendon interface, resulting in reformation of the enthesis. The demineralized bone fiber technology used in Tetrous products is licensed exclusively for use in sports medicine from TheraCell, an ISTO Biologics Company.
EnFix TAC is the second offering in the EnFix family of implants. It is available in two configurations, TAC-O and TAC-T, to accommodate the varied availability of bony real estate based on the size of the rotator cuff tear. While EnFix RC is designed to be used with suture anchors, the EnFix TAC options are specifically designed to deliver the same enthesis healing properties in a graft intended for use independent of a suture anchor or with all-suture anchors.
Since June 2023, when the EnFix implants were first commercially available, more than 400 grafts have been implanted in over 200 surgical cases in the US and Australia. With strong preclinical data and promising early clinical results showing healing at the bone-to-tendon interface, there is growing evidence supporting the applicability of the EnFix technology to address the unmet need for technology that can improve on the weak repair at the enthesis that is driving the high surgical failure rates in rotator cuff repairs.
Tetrous has completed the first surgical cases using EnFix TAC, its latest product that expands its line of EnFix implants to cover every surgical technique for rotator cuff repair. The EnFix product line is specifically designed to address Enthesis Failure Syndrome.
EnFix technology utilizes proprietary demineralized cortical bone fibers to...
Tetrous has completed the first surgical cases using EnFix TAC, its latest product that expands its line of EnFix implants to cover every surgical technique for rotator cuff repair. The EnFix product line is specifically designed to address Enthesis Failure Syndrome.
EnFix technology utilizes proprietary demineralized cortical bone fibers to yield an osteoinductive and osteoconductive implant designed to support optimal biologic healing at the bone-to-tendon interface, resulting in reformation of the enthesis. The demineralized bone fiber technology used in Tetrous products is licensed exclusively for use in sports medicine from TheraCell, an ISTO Biologics Company.
EnFix TAC is the second offering in the EnFix family of implants. It is available in two configurations, TAC-O and TAC-T, to accommodate the varied availability of bony real estate based on the size of the rotator cuff tear. While EnFix RC is designed to be used with suture anchors, the EnFix TAC options are specifically designed to deliver the same enthesis healing properties in a graft intended for use independent of a suture anchor or with all-suture anchors.
Since June 2023, when the EnFix implants were first commercially available, more than 400 grafts have been implanted in over 200 surgical cases in the US and Australia. With strong preclinical data and promising early clinical results showing healing at the bone-to-tendon interface, there is growing evidence supporting the applicability of the EnFix technology to address the unmet need for technology that can improve on the weak repair at the enthesis that is driving the high surgical failure rates in rotator cuff repairs.
Copy to clipboard 
